Exon 18 and/or exon 21 mutant EGFR selective inhibitor

• 收藏
• 分享

专利权人:

Taiho Pharmaceutical Co.; Ltd.

发明人:

ABE, Naomi,HASAKO, Shinichi

申请号：

AU2018325819

公开号：

AU2018325819A1

申请日:

2018.08.31

申请国别(地区):

AU

年份:

2020

代理人:

摘要：

An anti-tumor agent for treating patients with malignant tumors that express EGFR having at least one mutation selected from the group consisting of exon 18 G719X mutations, exon 18 E709X mutations, and exon 21 L861X mutations, the anti-tumor agent containing (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof. [X represents a discretionary amino acid residue.]

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/